Fiche centre
Princess Margaret Cancer Centre ( Site 0202)
Toronto — Canada
Essais liés2clinical trials
VilleTorontolocalisation
PaysCanadalocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT03765918
Essais cliniques associés
2| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Pembrolizumab 200 mg | Parkinson | Phase 3 | NCT03765918 | Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689) | ACTIVE_NOT_RECRUITING |
| Sacituzumab Tirumotecan | Parkinson | Phase 3 | NCT06841354 | A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) | RECRUITING |